ANGIOGENIN SECRETION FROM HEPATOMA CELLS ACTIVATES HEPATIC STELLATE CELLS TO AMPLIFY A SELF-SUSTAINED CYCLE PROMOTING LIVER CANCER

Cristina Bárcena[a], Milica Stefanovic[a], Anna Tutusaus[a], Guillermo A. Martinez-Nieto[a], Laura Martinez[a], Carmen García-Ruiz[a,b], Alvaro de Mingo[a], Juan Caballeria[b], José C Fernandez-Checa#[a,b,c], Montserrat Marí#[a,b], Albert Morales#[a,b]

[a]Department of Cell Death and Proliferation, IIBB-CSIC, IDIBAPS, Barcelona, Spain.

[b]Liver Unit-Hospital Clínic, CIBERehd. Barcelona, Spain.

[c]Research Center for ALPD and Cirrhosis, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.

Corresponding Authors: Albert Morales, amorales@clinic.ub.es, Montserrat Marí, monmari@clinic.ub.es or José C. Fernandez-Checa checa229@yahoo.com. Full contact information: Address: Centre Esther Koplowitz, C/ Rosselló 149-153, 4th Floor. 08036-Barcelona, Spain (Phone# +34-93-2275400 Ext.4545; Fax# +34-93-3129405).

Suppl. Fig. 1

A

	A	B	C	D	E	F	G	H
1	POS	POS	NEG	NEG	ANG	EGF	ENA-78	bFGF
2	POS	POS	NEG	NEG	ANG	EGF	ENA-78	bFGF
3	GRO	IFN gamma	IGF-1	IL-6	IL-8	Leptin	MCP-1	PDGF-BB
4	GRO	IFN gamma	IGF-1	IL-6	IL-8	Leptin	MCP-1	PDGF-BB
5	PLGF	RANTES	TGF beta 1	TIMP-1	TIMP-2	THPO	VEGF	VEGF-D
6	PLGF	RANTES	TGF beta 1	TIMP-1	TIMP-2	THPO	VEGF	VEGF-D
7	BLANK	BLANK	BLANK	BLANK	BLANK	BLANK	NEG	POS
8	BLANK	BLANK	BLANK	BLANK	BLANK	BLANK	NEG	POS

B

	A	B	C	D	E	F	G	H
1	POS	POS	NEG	NEG	ANGPT1	ANGPT2	PLG	Endostatin
2	POS	POS	NEG	NEG	ANGPT1	ANGPT2	PLG	Endostatin
3	G-CSF	GM-CSF	I-309	IL-10	IL-1 alpha	IL-1 beta	IL-2	IL-4
4	G-CSF	GM-CSF	I-309	IL-10	IL-1 alpha	IL-1 beta	IL-2	IL-4
5	I-TAC	MCP-3	MCP-4	MMP-1	MMP-9	PECAM-1	TIE-2	TNF alpha
6	I-TAC	MCP-3	MCP-4	MMP-1	MMP-9	PECAM-1	TIE-2	TNF alpha
7	uPAR	VEGF R2	VEGF R3	BLANK	BLANK	BLANK	BLANK	POS
8	uPAR	VEGF R2	VEGF R3	BLANK	BLANK	BLANK	BLANK	POS

Antibody array composition: A) Angiogenin, EGF, ENA-78, bFGF, GRO, IFN-gamma, IGF-1, IL-6, IL-8, Leptin, MCP-1, PDGF-BB, PLGF, RANTES, TGF beta 1, TIMP-1, TIMP-2, Thrombopoietin, VEGF-A, VEGF-D. B) Angiopoietin 1, Angiopoietin 2, Angiostatin, Endostatin, G-CSF, GM-CSF, I-309, IL-10, IL-1 alpha, IL-1 beta, IL-2, IL-4, I-TAC, MCP-3, MCP-4, MMP-1, MMP-9, PECAM-1, Tie-2, TNF alpha, uPAR, VEGFR2, VEGFR3.

Suppl. Fig. 2

	Cirrhotic Decompensated (n=9)	Cirrhotic Compensated (n=7)	Alcoholic (n=9)	Reference values
Age	51±2	58±2	48±4	-
Billirubin (mg/dl)	2.31±0.66 *	1.46±0.56 *	0.79±0.16	0.2 - 1.0
Albumin (g/l)	32.3±2.6 *	42.1±1.6	44.4±0.6	35 - 50
Quick (%)	61.6±8.0 *	77.6±7.5	97.7±1.8	70 - 100
MELD	4.4±1.8	10.4±1.6	7.1±0.4	6
Creatinin (mg/dl)	0.97±0.10	1.02±0.08	0.83±0.06	0.6 - 1.2
AST (U/l)	50±17 *	29±3	21±4	10 - 40
ALT (U/l)	24±4	25±2	23±4	10 - 35
GGT (U/l)	115±43 *	58±15 *	38±19	5 - 40

Biochemical data from the patient's serums analyzed for angiogenin concentration. Reference ranges for normal individuals are indicated for each parameter (right column) according to Hospital Clinic Core Lab (Barcelona, Spain).

Suppl. Fig. 3



HepG2 cells were treated with neomycin at different doses (0 to 2 mM) for one week and cell growth was quantitated by MTT assay. No significant differences were found between groups.